FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Keeps Hold Opinion On Adss Of Bhp Group

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price to USD86 (up from USD83), valuing BHP at 6.80x FY 26 EV/EBITDA, or 19% above its three-year historical mean, reflecting near-term commodity tailwinds from copper and iron ore. Management maintains FY 26 copper guidance and now expects production in the upper half of the range, supported by Escondida's strong performance with record material mined and lowered unit cost guidance to USD1.00-USD1.20/lb (from USD1.20-USD1.50/lb). We remain optimistic on copper as the global market is forecast to shift to a deficit of approximately 150k tonnes in 2026, supported by electrification and digital infrastructure demand. However, we are cautious on iron ore due to oversupply concerns from Simandou production and sluggish Chinese steel demand. The successful resolution of BHP's contract dispute with CMRG eliminates volume uncertainty and should stabilize core iron revenue from China. We forecast EPADS at USD5.24/USD5.48 in FY 26/FY 27 (up from USD5.22/USD5.32).

Related Articles

Australia

Mizuho Securities Raises Price Target on Apellis Pharmaceuticals to $41 From $20, Maintains Neutral Rating

Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.95, Change: $-0.05, Percent Change: -0.11%

$APLS
Research

Mizuho Securities Downgrades Terns Pharmaceuticals to Neutral From Outperform, Trims Price Target to $53 From $54

Terns Pharmaceuticals (TERN) has an average rating of hold and mean price target of $53, according to analysts polled by FactSet.

$TERN
Research

Research Alert: CFRA Reiterates Buy Opinion On Shares Of Booking Holdings Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price by $8 to $196, 19x our 2026 EPS estimate (unchanged) and a discount to its 23x five-year average forward multiple, reflecting geopolitical risks. We lower our 2026 EPS to $10.33 from $10.74 and 2027's to $11.58 from $12.07, primarily reflecting lower gross bookings growth from the Middle East conflict. We maintain our Buy opinion as shares are undervalued given long-term competitive strengths and temporary geopolitical headwinds. The company's Connected Trip platform and Genius loyalty program are supporting higher-margin direct bookings, suggesting AI initiatives are strengthening consumer engagement rather than disintermediating the platform. Strong free cash flow supports future shareholder returns, including $3.6 billion in Q1 buybacks. While the Middle East conflict will impact Q2 bookings, BKNG has a history of seeing travel rebound following geopolitical or economic disruptions. U.S. room night growth accelerated in Q1 to a low-teens range, providing near-term momentum.

$BKNG